Strategic Financial Concepts LLC Purchases Shares of 10,958 Illumina, Inc. (NASDAQ:ILMN)

Strategic Financial Concepts LLC acquired a new position in shares of Illumina, Inc. (NASDAQ:ILMN - Free Report) in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund acquired 10,958 shares of the life sciences company's stock, valued at approximately $1,464,000.

A number of other institutional investors also recently made changes to their positions in ILMN. Bleakley Financial Group LLC acquired a new stake in shares of Illumina in the fourth quarter valued at approximately $751,000. Zacks Investment Management acquired a new stake in shares of Illumina in the third quarter valued at approximately $2,924,000. Van ECK Associates Corp raised its position in shares of Illumina by 17.5% in the fourth quarter. Van ECK Associates Corp now owns 152,265 shares of the life sciences company's stock valued at $20,347,000 after buying an additional 22,718 shares in the last quarter. Allworth Financial LP raised its position in shares of Illumina by 720.7% in the fourth quarter. Allworth Financial LP now owns 7,132 shares of the life sciences company's stock valued at $1,001,000 after buying an additional 6,263 shares in the last quarter. Finally, Freemont Management S.A. acquired a new stake in shares of Illumina in the third quarter valued at approximately $1,565,000. Institutional investors own 89.42% of the company's stock.

Illumina Trading Down 3.1 %

Shares of Illumina stock traded down $3.00 during trading on Friday, hitting $94.20. The company's stock had a trading volume of 4,225,715 shares, compared to its average volume of 2,592,243. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.77 and a quick ratio of 1.42. Illumina, Inc. has a 52 week low of $93.50 and a 52 week high of $156.66. The stock has a market cap of $14.92 billion, a price-to-earnings ratio of -12.27, a price-to-earnings-growth ratio of 1.70 and a beta of 1.10. The stock has a 50-day moving average price of $127.98 and a two-hundred day moving average price of $134.01.

Illumina (NASDAQ:ILMN - Get Free Report) last issued its quarterly earnings data on Thursday, February 6th. The life sciences company reported $0.86 earnings per share for the quarter, missing the consensus estimate of $0.92 by ($0.06). Illumina had a positive return on equity of 13.37% and a negative net margin of 27.95%. Equities research analysts anticipate that Illumina, Inc. will post 4.51 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of equities research analysts have recently weighed in on ILMN shares. Guggenheim dropped their price target on shares of Illumina from $170.00 to $150.00 and set a "buy" rating for the company in a research report on Friday, February 7th. Canaccord Genuity Group lowered their price objective on shares of Illumina from $145.00 to $135.00 and set a "hold" rating for the company in a research report on Friday, February 7th. Robert W. Baird boosted their price objective on shares of Illumina from $124.00 to $139.00 and gave the company a "neutral" rating in a research report on Wednesday, November 6th. Piper Sandler boosted their price objective on shares of Illumina from $185.00 to $190.00 and gave the company an "overweight" rating in a research report on Monday, February 10th. Finally, UBS Group boosted their price objective on shares of Illumina from $133.00 to $145.00 and gave the company a "neutral" rating in a research report on Tuesday, November 5th. One equities research analyst has rated the stock with a sell rating, eight have issued a hold rating, eleven have issued a buy rating and two have given a strong buy rating to the company. According to MarketBeat, the stock has an average rating of "Moderate Buy" and an average price target of $159.45.

Illumina Company Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.